1740-88-1

Usage

Uses

Used in Medicinal Chemistry and Pharmaceutical Research:
5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole is utilized as a building block in the synthesis of complex organic molecules, particularly for the development of new drugs and therapeutic agents. Its unique structure allows for versatile chemical modifications, making it a valuable component in medicinal chemistry.
Used in Drug Development:
In the pharmaceutical industry, 5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole is employed as a key intermediate for creating novel drug candidates. Its presence in molecular structures can impart specific biological activities, contributing to the discovery of new treatments for various diseases.
Used in Materials Science:
5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole may also find applications in materials science, where its chemical properties could be leveraged to develop new materials with unique characteristics, such as improved stability or specific interactions with other molecules.
Used in Agrochemicals:
In the agrochemical industry, 5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole could be used as a starting material for the synthesis of new pesticides or other agrochemicals, potentially leading to more effective and environmentally friendly products.
Given the diverse potential applications of 5-bromo-2-(chloromethyl)-1H-benzo[d]imidazole, it is an important target for further study and development across multiple scientific disciplines.

Upstream product

• 79-11-8 chloroacetic acid 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 540516-28-7 (5-bromo-1H-benzo[d]imidazol-2-yl)methanol 
• 36743-66-5 ethyl chloroacetimidate hydrochloride 

Downstream Products

• 956283-22-0 (5-bromo-1H-benzimidazol-2-ylmethyl)-triphenyl-phosphonium chloride 
• 1225045-55-5 N-[(5-bromo-1H-benzimidazol-2-yl)methyl]-2-chloroaniline 
• 1178363-80-8 N-[(5-bromo-1H-benzimidazol-2-yl)methyl]-3-chloroaniline 
• 1183502-57-9 N-[(5-bromo-1H-benzimidazol-2-yl)methyl]aniline 
• 1225045-57-7 N-[(5-bromo-1H-benzimidazol-2-yl)methyl]-4-methoxyaniline 
• 1183314-68-2 N-[(5-bromo-1H-benzimidazol-2-yl)methyl]-4-methylaniline 
• 1033624-86-0 5-bromo-2-(4-trifluoromethyl-phenoxymethyl)-1H-benzoimidazole 

Relevant academic research and scientific papers

INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents

A series of novel benzimidazole quinolones as potential antimicrobial agents were designed and synthesized. Most of the prepared compounds exhibited good or even stronger antimicrobial activities in comparison with reference drugs. The most potent compound 15m was membrane active and did not trigger the development of resistance in bacteria. It not only inhibited the formation of biofilms but also disrupted the established Staphylococcus aureus and Escherichia coli biofilms. It was able to inhibit the relaxation activity of E. coli topoisomerase IV at 10 μM concentration. Moreover, this compound also showed low toxicity against mammalian cells. Molecular modeling and experimental investigation of compound 15m with DNA suggested that this compound could effectively bind with DNA to form a steady 15m-DNA complex which might further block DNA replication to exert the powerful bioactivities.

Synthesis and evaluation of selected benzimidazole derivatives as potential antimicrobial agents

A library of 53 benzimidazole derivatives, with substituents at positions 1, 2 and 5, were synthesized and screened against a series of reference strains of bacteria and fungi of medical relevance. The SAR analyses of the most promising results showed that the antimicrobial activity of the compounds depended on the substituents attached to the bicyclic heterocycle. In particular, some compounds displayed antibacterial activity against two methicillin-resistant Staphylococcus aureus (MRSA) strains with minimum inhibitory concentrations (MICs) comparable to the widely-used drug ciprofloxacin. The compounds have some common features; three possess 5-halo substituents; two are derivatives of (S)-2-ethanaminebenzimidazole; and the others are derivatives of one 2-(chloromethyl)-1Hbenzo[ d]imidazole and (1H-benzo[d]imidazol-2-yl)methanethiol. The results from the antifungal screening were also very interesting: 23 compounds exhibited potent fungicidal activity against the selected fungal strains. They displayed equivalent or greater potency in their MIC values than amphotericin B. The 5-halobenzimidazole derivatives could be considered promising broad-spectrum antimicrobial candidates that deserve further study for potential therapeutic applications.

BENZIMIDAZOLE TRPV1 INHIBITORS

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Benzimidazole Modulators of VR1

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.